Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of high-dose Tanreqing injection for COVID-19
ChiCTR2000029432Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Guangzhou University of Chinese Medicine
- Start
- Feb 2020
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tanreqing in coronavirus disease 2019 (COVID-19) and pneumonia, sponsored by First Affiliated Hospital of Guangzhou University of Chinese Medicine. Primary endpoints: Time for body temperature recovery and Chest X-ray absorption. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
tanreqing
03
Conditions
coronavirus disease 2019 (COVID-19)pneumonia
Beyond the preview
Go deeper on ChiCTR2000029432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029432.